SUPPRESSION OF PLASMA ANDROGENS BY SPIRONOLACTONE IN CASTRATED MEN WITH CARCINOMA OF THE PROSTATE

WALSH, PATRICK C.
SIITERI, PENTTI K.

From the Department of Urology and Clinical Investigation Center, Naval Hospital, San Diego, California
Departments of Obstetrics-Gynecology and Biochemistry, University of Texas Southwestern Medical School, Dallas, Texas

Accepted for publication December 20, 1974.

^*Requests for reprints: Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21205.

Journal of Urology 114(2):p 254-256, August 1975. | DOI: 10.1016/S0022-5347(17)67001-0

Spironolactone, an inhibitor of androgen synthesis, has been administered to castrated men with metastatic carcinoma of the prostate. Plasma levels of testosterone, androstenedione and dehydroepiandrosterone were significantly decreased. These data indicate that spironolactone suppresses adrenal androgen production and suggest that it may be of benefit in the treatment of orchiectomized patients with advanced carcinoma of the prostate.